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Abstract
Background: Plasmodium falciparum resistance to anti-malarial drugs remains a major obstacle to the control of
malaria. In 2001 Tanzania replaced chloroquine (CQ) with sulphadoxine-pyrimethamine (SP) as first-line drug, which
in turn was replaced by artemisinin combination therapy in 2006. SP has however, continued to be used in intermittent
preventive treatment of malaria in pregnancy (IPTp) despite reports of high levels of resistance to SP due to the lack of
alternatives to SP for IPTp. Recent reports have indicated recovery of CQ-susceptibility in Malawi, Kenya, Mozambique,
and Tanzania based on the prevalence of wild types at codon 76 of the Pfcrt gene in indigenous P. falciparum
populations. The current prevalence of this Pfcrt-76 CQ resistance marker from six regions of Tanzania mainland is
hereby reported.
Methods: DNA extracted from filter-paper dried blood spots and rapid diagnostics kit strips collected from finger-prick
blood were used to genotype the Pfcrt-76 resistance marker using PCR-RFLP. Data from previously published studies
were used to generate CQ susceptibility recovery trends using logistic regression model.
Results: Seven hundred and forty one (741) samples were genotyped. The current frequency of the CQ-susceptible
Pfcrt-K76 was above 92% and did not differ between regions in Tanzania (χ2 = 2.37; p = 0.795). The K76 allelic prevalence
was between 85.7 and 93% in regions (χ2 = 7.88, p = 0.163). The CQ resistance recovery trends showed regional variability
that may be caused by differences in malaria transmission intensity, but overall the trends converge as the susceptibility
levels in all regions approach >90%.
Conclusions: CQ withdrawal in Tanzania has resulted into >90% recovery of susceptibility in ten years of withdrawal.
These findings are in support of the search for CQ-based combination drugs as a possible future alternative to SP for IPTp
in places where full recovery of CQ-susceptibility will be evident.
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Background
Chloroquine (CQ) was the cornerstone of anti-malarial
treatment in Africa for almost 50 years but due to resist-
ance in the malaria parasite Plasmodium falciparum,
CQ was abandoned [1]. Malawi was the first African
country to replace CQ in 1993 [2], followed by Kenya in
1998 [3] and Tanzania in 2001 [4].
In Tanzania CQ was replaced by sulphadoxine-
pyrimethamine (SP) as first-line treatment and amodia-
quine (AQ) as second-line for uncomplicated malaria
while quinine remained the third-line for complicated
malaria [5]. The CQ policy change was mainly based on
in vivo efficacy studies that had reported as high as 52%
treatment failure by 1999 [5]. Resistance to SP in the
East African region had already emerged even before it
was declared first-line drug [5-7], thus in Tanzania, SP
was an interim solution that lasted for only five years
and by the end of 2006 it was replaced with the current
artemisinin-based combination therapy (ACT) [8]. Al-
though ACT has been largely adopted by most African
countries, SP has continued to be used in intermittent
preventive treatment of malaria in children (IPTc) and
pregnant women (IPTp). The level of resistance to SP
due to its continued use has continued to spread, threat-
ening the future of SP-IPTp [9-12]. This has necessitated
an urgent search for an alternative to SP and several
options are under evaluation including combinations
that include CQ [13].
CQ-resistant falciparum malaria is caused by mutations
on two genes, the P. falciparum CQ resistance transporter
(Pfcrt) and multidrug resistance transporter-1 (Pfmdr1)
both located on the food vacuole of the parasite. While
wild-type Pfmdr1 is thought to transport and accumulate
CQ into the parasites food vacuole, mutations N86Y,
S1034C, N1042D, and D1246Y abolish this transport
leading to reduced CQ-sensitivity reviewed in [14].
Polymorphisms of the mutations have also been linked to
resistance or sensitivity to other antimalarials. On the other
hand, the CQ transporter Pfcrt is a stronger predictor of
CQ resistance than Pfmdr1. Mutations at codons 72 to 76
leading to amino acids replacements from Cysteine-Valine-
Methionine-Asparagine-Lysine (CVMNK) to two major
haplotypes Cysteine-Valine-Isoleucine-Glutamate-Threonine
(CVIET) prevalent mostly in Africa and Serine-Valine-
Methionine-Asparagine-Threonine (SVMNT) in South-East
Asia have been associated with CQ resistance [15]. One of
the mutations, the Pfcrt-K76T, is directly linked with both
in-vitro and clinical resistance and is thus used as a bio-
marker of CQ resistance [16]. Following CQ withdrawal
in Malawi, emergency of parasites carrying the CQ-
sensitive Pfcrt-76 with 100% clinical efficacy was reported
just eight years after the policy change [2]. Similar findings
have been reported in other countries. Two studies in
Tanzania reported restoration of CQ-sensitive Pfcrt-76
from 17.1 to 50.7% in five years [17] and from 48 to 89.6%
in seven years [18]. In Kenya the restoration was much
slower than in Malawi and Tanzania, raising from 5 to
40% in 13 years [3]. This study has investigated
the current status of CQ resistance based on Pfcrt-76T
marker in six regions located in the four major regional
zones of Tanzania and estimated the selection coefficients
in the regions.
Methods
Samples used in this study were obtained through colla-
boration with ongoing studies in six regions of mainland
Tanzania between June 2010 and August 2011. Except
for the Coastal region where the sample involved
pregnant women attending the Kibiti health centre for
intermittent preventive treatment of malaria, all other
samples were collected from all-age groups. Finger-prick
blood on filter paper (Whatman-3) or rapid diagnostic
test kits (Mwanza samples only) from febrile patients
attending various health facilities in the respective
regions were collected after patient’s or children’s guard-
ians had consented to the use of their blood samples for
malarial genetic studies. The study sites include Mwanza
(Misungwi district) and Kagera (Muleba district) around
Lake Victoria in the north-western zone, Tanga (Bondo
village) in the northeastern zone, Mtwara (Tandahimba
and Mtwara-Urban) and Coastal Region (Kibiti-Rufiji) in
the southeastern zone and Mbeya (Kyela and Rungwe
districts) in the south-western zone. The malaria-
positive rapid diagnostic test (RDT) strips or dried filter-
paper blood spots were stored in desiccant at room
temperature. Malaria parasite DNA was extracted using
chelex-100 method as described previously [19]. Geno-
typing for Pfcrt-K76T was performed using PCR-RFLP
methods described by Schneider and others [20]. All
PCR reagents and restriction endonucleases were pur-
chased from New England Biolabs (Ipswich, MA, USA).
Primers were purchased from Biolegio (Nijmegen, The
Netherlands).
Previous publications on Pfcrt-K76T in Tanzania were
obtained by searching PubMed database with keywords
“malaria Tanzania”; “pfcrt Tanzania”, “drug resistance
Tanzania” and “chloroquine Tanzania”. Allele frequencies
of Pfcrt-76 were calculated as the proportion of samples
carrying the wild-type form (K76) or mutant form
(76T) out of the total of all samples carrying the mutant
form only and the wild-type form only. Prevalence was
calculated by first adding the number of samples carry-
ing mixed infections to both wild-type only and mutants
only, thereby obtaining a new ‘n’ (which includes the
mixed infections twice). Prevalence of wild-type and
mutant allele was then calculated as the percentage of
wild-type plus mixed infection or mutants plus mixed
infection out of the new ‘n’.
Mohammed et al. Malaria Journal 2013, 12:415 Page 2 of 7
http://www.malariajournal.com/content/12/1/415
Comparison of genotype prevalence between regions
was performed with a six-sample test for equality of pro-
portions using Pearson's chi-square test statistic. Logistic
regression was used to compare trends of decline in
prevalence of Pfcrt-76T allele and to estimate selection
coefficients (s) using R version 2.15.2. To do this, a logis-
tic regression was performed on the data for each region
separately. The number of generations per year was
taken to be three, as established elsewhere [3]. The
s-coefficients are the slopes of the regression lines in the
resulting model, and express the proportional change
per generation in the ratio of resistant to susceptible
alleles. The analysis was performed using R's generalised
linear model function with the logit link function and a
binomial response. Graphical post-production was per-
formed with Apple Grapher software. The study received
ethical approval from the Kilimanjaro Christian Medical
University College Ethical Board subsequent to the
National IRB (NIMR) approval obtained in the collaborat-
ing projects.
Results
Prevalence of Pfcrt-K76T in six regions of Tanzania
Seven hundred and forty one (741) samples were geno-
typed at codon 76 of the Pfcrt-gene. Of the total sample
set, 672 contained single K76 (susceptible) allele, 42
contained the single 76T (resistant) allele while 27
contained mixed K76/76T (susceptible/resistant) alleles.
When mixed infections were excluded, the frequency of
the susceptible K76 allele in the regions ranged from 92.1
to 97.1% (Table 1). This distribution was not significantly
different between the regions (χ2 = 2.38; p = 0.795). Fur-
thermore, when mixed infections were included in cal-
culating allelic prevalence, there were slight differences in
prevalence of the susceptible K76 allele between the
regions ranging from 85.7% (Mtwara region) to 93.5%
(Coastal region) but these differences were again not sig-
nificant (χ2 = 7.88, p = 0.163) (Table 1). Overall these re-
sults indicated that the distribution of the Pfcrt-K76T
resistance marker does not differ significantly between the
six regions and that the current prevalence of CQ-
susceptible allele is between 85.7 and 93.5%.
Comparison of current Pfcrt-76T prevalence with previ-
ously published data in Tanzania
A total of eleven papers were retrieved from PubMed.
These reports documented frequency of the single K76
or 76T infections and the mixed infections. Allelic fre-
quencies were recalculated from these reports and were
used to determine the CQ resistance trends. Table 2
summarizes the data that was used in computing decline
in CQ resistance trend lines (Figure 1).
From the trend lines the following observations are
made: (i) the Mtwara and Mbeya trends are based on
two data points which are several years apart and should
be interpreted with caution; (ii) the Mwanza trend is
based on three measurements in a short time span
(2010–2011) and generalization of its selection coeffi-
cient beyond this period has been done with caution as
well; (iii) the Tanga and especially the Coastal regions
have well-fitting data across a wide time range. For
Coastal region the recalculated prevalence of 27.9% in
2004 [23] (Table 2) was a remarkable outlier, thus was
excluded from the analysis; and, (iv) the data used in
these trends were collected from different sites within
the regions.
Intraregional data from the Tanga and Coastal regions
suggest considerable intraregional variation therefore the
trends must not be seen as applying to homogeneous
regions but rather as general trends within the regions.
The trends indicate that decline of CQ resistance started
at different moments in different regions, with Mtwara
crossing the 80% mark in early 1999, Coastal region at
the start of 2001 and Tanga in late 2003. By this time,
levels in Coastal and Mtwara were already down to 62%
and 47%, respectively. Decline in Tanga, although it
started later, was much swifter (s = −0.139) than in
Coastal (s = −0.104) and Mtwara (s = −0.102). The first
region to fall below the 10% resistant mutants mark was
Mtwara in early 2010. The other regions followed and
all had crossed the 10% mark by the start of 2012.
Projections of the Pfcrt-76T prevalence to decrease
beyond 1%
Projecting to mid-2013 levels, the current resistance
levels could be in the range of 3.5 to 6.3%. However, due
to their asymptotic nature, it will not be until late 2016
when the first trend line (Mbeya) is expected to cross
the 1% line and mid-2019 when the prevalence of resist-
ance in all regions will be below 1%.
Discussion
In Tanzania, with the official ban of CQ in 2001, CQ has
now been out of use for almost 12 years although self-
Table 1 Distribution of Pfcrt K76T resistance marker in
six regions of Tanzania
Frequency of K76T Prevalence of K76
Region K76 (%) 76T (%) Mixed n %
Tanga 108 (94.7) 6 (5.3) 2 116 93.2
Coastal 130 (93.5) 9 (6.5) 0 139 93.5
Mtwara 66 (97.1) 2 (2.9) 3 71 93.2
Kagera 82 (92.1) 7 (7.9) 8 97 85.7
Mwanza 150 (93.2) 11(6.8) 10 171 88.4
Mbeya 136 (95.1) 7 (4.9) 4 147 92.7
Overall 672 (94.3) 42 (5.7) 27 741 91
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Figure 1 CQ resistance trends by Pfcrt76T between 1999 and 2012 in Tanzania. Trend lines represent Pfcrt76T mutation decrease with
time in years; S = selection coefficient; On Y-axis: percentage prevalence; X-axis: years.
Table 2 Recalculated prevalence of Pfcrt-76T (mutant Pfcrt) from previous studies in Tanzania
Region Sites Reported frequency % Mixed Recalculated prevalence (%) Year Number of samples (n) Reference
Mtwara Masasi 78.9 13 79.7 1999 71 [20]
Mbeya Matema and Mbeya urban 43 6 46.7 2005 86 [21]
Coastal Kibaha 86.2 1 86.2 1998 51 [22]
Bagamoyo 64.5 16 70.6 2002 76 [23]
16 29 27.9 2004 175
Bagamoyo 52 23 60.8 2004 102 [18]
28.6 11 41.6 2006 49
18.3 43 30 2007 257
16.6 28 27.4 2008 187
19.4 2 24.2 2010 31
11.4 5 14.4 2011 123
Bagamoyo 51.9 23 60.8 2004 102 [24]
Tanga Muheza 82.9 6 85 2003 41 [25]
Korogwe 70.5 42 76.7 2003 156 [26]
Korogwe 70.3 42 77.4 2003 155 [17]
63.1 55 72.4 2004 163
67.1 24 72 2007 73
49.3 21 75 2006 76
Mwanza Igombe 16.8 0 16.8 2010 77 [27]
Igombe 11.1 0 11.1 2011 90 [28]
Prevalence was recalculated as a percentage of the total when the number of mixed infections is added to both single wild types and mutants.
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medication might have continued for a few years later. A
survey done in 2002, at about one year post-policy
change, reported detection of CQ in only 5% of children
aged under-five in Kibaha, Coastal region [29]. At the
time of its withdrawal the prevalence of the Pfcrt-76T
resistance marker is estimated to have been over 80%
although this has only been documented in Tanga,
Coastal and Mtwara regions (Table 2) [20,22,26]. This
study presents the current Pfcrt-76T prevalence in six
representative regions of Tanzania.
The current frequency of CQ-susceptible Pfcrt-K76
marker (over 90%) in all regions and the allelic preva-
lence beyond 85% in Mwanza and Kagera and over 92%
in the rest indicate a rapid decline of the Pfcrt-76T
marker in Tanzania. While there were no recent data for
Mtwara, Mbeya, Tanga and Kagera regions, the results
are comparable to the recent findings in Mwanza and
Coastal regions where 88.9 and 88.6%, respectively, were
reported for Pfcrt-K76 in 2011 [18,28].
CQ resistance trends were compared between the
regions. The trends have shown a recovery of CQ
susceptibility from <20 to >90% in ten years. This trend
is comparable to findings in other countries such as
Malawi, Mozambique and Kenya. In Malawi recovery of
the susceptible Pfcrt-K76 from <15 to 100% within
13 years and in Mozambique from <5 to 80% within five
years of CQ withdrawal were reported [2,30] while in
Kenya a much slower recovery was observed between
1993 to 2006 from 5 to 40%, which is about 13 years
after policy change [3]. In Uganda the situation has been
very different. Studies conducted in Mulago Hospital,
Kampala and Rakai District, southern Uganda, reported
between 100 and 98.7% CQ-resistant Pfcrt-76T in 2008,
about eight years post-CQ replacement due to incomplete
CQ withdrawal [31,32], while a recent study in Iganga
District, southern Uganda reported 100% resistant Pfcrt-
76T [27]. Such discrepancies are partly explained by dif-
ferences in drug policy implementation between countries,
although other factors such as differences in malaria
transmission patterns and intensity may play a role.
Malawi was the first to replace CQ with SP in 1993
followed by Kenya in 1998, Uganda in 1999, Tanzania in
2001 and Mozambique in 2004 [3,4,33,34]. However, in
Kenya and Tanzania amodiaquine, a close analogue to
CQ, was introduced as second line to SP, while in Uganda
CQ was replaced with CQ-SP combination until 2006,
when it was replaced by ACT. From 2006 to 2007 a de-
mographic health survey and multiple indicator cluster
survey in 21 African countries documented CQ use as 0.8,
0.5, 45.5 and 37% in Malawi, Tanzania, Uganda, and
Somalia, respectively [35]. Furthermore, in Rakai District,
southern Uganda, a study done in 2007 on “Prescription
practices for malaria in rural Uganda” reported prescrip-
tion of CQ only and CQ+ SP at 2.1 and 3.6%, respectively
[36]. CQ has been available as home pack CQ-SP formula-
tion for several years in Uganda [37,38]. Likewise in
Somalia where CQ was replaced with artesunate + SP
combination (AS-SP) in 2005, in 2007 37.7% of public
health facilities and 53.1% of private pharmacies were still
prescribing CQ as first line [39]. This evidence shows that
the lack of synchronized treatment policy across countries
has resulted in diversified parasite populations in counties
that share the same geographical location.
From these findings, a projected >99% CQ susceptibil-
ity by 2019 would be expected under the same condi-
tions that led to the current trends. In Kilifi, Kenya
where recovery of CQ susceptibility was much slower, a
100% recovery of CQ susceptibility was predicted by
2026. However, factors such as the declining malaria
transmission intensity with consequently reduced drug
pressure, introduction of amodiaquine-based ACT and
human migration factors may affect such predictions.
These findings demonstrate the challenge that African
countries have, to achieve the goal of malarial eradica-
tion. Now that there is growing evidence for selection of
parasites with increased ACT-tolerance [30,40], drugs
such as CQ, which is known for its safety, low cost and
availability, are good future alternatives for uncompli-
cated malaria when such drugs are withdrawn for a
given period of time. Studies have shown that even in
the presence of Pfmdr1 mutations CQ can remain effect-
ive in the absence of Pfcrt-76T [2]. However, with the
current situation where there is diversified treatment
policy across countries, such options may be very
narrow. It will be a great challenge to re-introduce CQ
in countries where CQ susceptibility has been restored if
neighbouring countries still have high levels of resist-
ance. CQ re-introduction will also require regulation of
the market against CQ monotherapy. There is a need to
harmonize treatment policies across countries or within
WHO regions.
Regional differences in selection coefficients were
observed although these could not be compared directly.
Samples from different sites within the regions were
included and correction for intraregional differences in
transmission intensity and drug use could not be done.
However, regardless of the different regional rates of
recovery, the trends clearly are converging, indicating
overall homogeneity in the selection pressure for the CQ
susceptible marker. This is furthermore supported by
the lack of a statistically significant difference in the
current prevalence across the country, and is similarly
observed in Mozambique where different zones showed
different patterns of Pfcrt-K76 recovery [34].
Currently there are ongoing trials to determine the use
of CQ in combination with other drugs, such as azithro-
mycin [13]. With the currently recommended ACT that
has demonstrated effectiveness in clearing multidrug-
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resistant strains of P. falciparum, full recovery of CQ
efficacy is a possibility if countries consider withholding
CQ use for some years to reverse selection pressure. The
WHO has continued to recommend SP-IPTp [41]. The
levels of SP resistance have continued to rise and already
reports show no or reduced effectiveness of SP-IPTp
[10,42]. A recent study in Korogwe, Tanzania reported
association of a specific SP-resistant mutation with low
birth weight [43]. There is a need for an alternative to
SP. Furthermore, as malaria transmission continues to
decrease, moving towards elimination will pose the add-
itional challenge of reduced immunity due to reduced
malaria exposure in all age groups. This may elevate the
chance of pregnant mothers developing clinical disease
even at very low parasitaemia, thus requiring effective
drugs other than SP for IPTp.
Conclusions
This report documented more than 90% recovery of CQ
susceptibility based on Pfcrt-76 biomarker in Tanzania.
This is a rapid recovery from the >85% CQ resistance
before CQ withdrawal in 2001. This trend has been
observed in other countries and provides evidence that
removal of drug pressure can result into full recovery of
efficacy to drugs that were previous rendered ineffective
due to resistance. CQ in combination with another anti-
malarial drug remains a promising future alternative to
SP in IPTp as a combinational drug if adequate mea-
sures are taken to harmonize malaria treatment policy
across countries and restrict any continued use of CQ as
a monotherapy. Careful evaluation should be done to
determine the appropriate CQ combination without
reversing the current trends.
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